{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Duration of response was defined as the time from the first CR or PR until disease progression (assessed per RECIST v1.1 by the investigator) or death from any cause, whichever occurred earlier. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.","groups":[{"description":"Participants received INCB099280 50 milligrams (mg) once daily (QD) plus adagrasib 400 mg twice daily (BID) for up to 2 years.","id":"OG000","title":"INCB099280 50 mg QD Plus Adagrasib 400 mg BID"},{"description":"Participants received INCB099280 100 mg BID plus adagrasib 400 mg BID for up to 2 years.","id":"OG001","title":"INCB099280 100 mg BID Plus Adagrasib 400 mg BID"}],"populationDescription":"Full Analysis Set. As specified in the Statistical Analysis Plan, analysis of duration of response was to be performed only if the number of responders was ≥5.","reportingStatus":"POSTED","timeFrame":"up to 470 days","title":"Duration of Response","type":"SECONDARY"}